Holen Sie sich die Stockscreener-App
57.72
0.17%
-0.10
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Is RAPT Therapeutics Inc a speculative investmentStop Loss & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Small Cap Stocks To Watch NowFebruary 13th - MarketBeat
Best Pharmaceutical Stocks To Follow TodayFebruary 13th - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Growth in Short Interest - MarketBeat
Can RAPT Therapeutics Inc. withstand a market correctionCPI Data & AI Based Buy and Sell Signals - mfd.ru
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? - Morningstar
Top Pharmaceutical Stocks To ConsiderFebruary 10th - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Why did RAPT stock surge 63% in pre-market today? - MSN
Pharma deal value falls in January 2026 amid lower M&A activity: GlobalData - Express Pharma
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders - marketscreener.com
RAPT Therapeutics Proposed Sale to GSK Under Investigation - Intellectia AI
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc.RAPT - ChartMill
Rapt Therapeutics (NASDAQ:RAPT) Hits New 12-Month HighHere's Why - MarketBeat
GSK's Acquisition Highlights Trend Towards Convenience-Focused D - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger-JHG, FOLD, RAPT, and EXAS - The Malaysian Reserve
GSK to buy RAPT Therapeutics in $2.2 billion deal for promising food allergy therapy - MSN
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations - GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—JHG, FOLD, RAPT, and EXAS - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS - Sahm
Rapt Therapeutics stock reaches 52-week high at $57.71 By Investing.com - Investing.com Nigeria
Biggest stock movers Tuesday: NVDA, RAPT, MMM and more - MSN
Rapt Therapeutics (NASDAQ:RAPT) Reaches New 12-Month HighStill a Buy? - MarketBeat
Rapt Therapeutics stock reaches 52-week high at $57.71 - Investing.com
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Sahm
RAPT Therapeutics jumps 64% after GSK tables $2.2bn takeover proposal - MSN
GSK acquires RAPT Therapeutics for $2.2bn - MSN
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge - Yahoo Finance
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Biggest stock movers Tuesday: NVDA, RAPT, and more - MSN
Rapt Therapeutics stock hits 52-week high at $57.62 By Investing.com - Investing.com Nigeria
RAPT Stock Soars On GSK Takeover Deal Valuing Company At $2.2 Billion - Stocktwits
RAPT Therapeutics (RAPT) Receives Downgrade to Equal-Weight by B - GuruFocus
Barclays Reaffirms Equal Weight Rating for Rapt Therapeutics (NASDAQ:RAPT) - MarketBeat
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout - Finviz
Rapt Therapeutics stock hits 52-week high at $57.62 - Investing.com
RTW Biotech Opp.GSK to acquire RAPT Therapeutics - Research Tree
Leerink Partners Downgrades RAPT Therapeutics(RAPT.US) to Hold Rating, Cuts Target Price to $58 - 富途牛牛
Rapt Therapeutics (RAPT) Stock: Pharma Giant GSK Pays $2.2 Billion for Biotech - Blockonomi
GSK acquires food allergy firm Rapt Therapeutics for $2.2bn - European Pharmaceutical Review
GSK acquires Rapt Therapeutics stock for $2.2 billion as Leerink downgrades - Investing.com Nigeria
GSK to buy Rapt Therapeutics in deal valued at $2.2B - MSN
GSK acquires Rapt Therapeutics stock for $2.2 billion as Leerink downgrades By Investing.com - Investing.com Canada
RTW Biotech welcomes GSK deal to buy RAPT Therapeutics - marketscreener.com
Rapt Therapeutics (NASDAQ:RAPT) Downgraded to "Hold" Rating by Clear Str - MarketBeat
Rapt Therapeutics (RAPT) Stock: GSK Snaps Up Biotech in $2.2 Billion Deal - CoinCentral
GSK enters agreement to acquire RAPT Therapeutics - marketscreener.com
UK: GSK agrees acquisition of RAPT Therapeutics in transaction valued at US$2.2bn - Investors in Healthcare
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):